NCT01689727 is a Phase 2 clinical trial of Technetium Tc 99m EC20 in Pituitary Tumors, sponsored by Endocyte.

Who is sponsoring NCT01689727?

NCT01689727 is sponsored by Endocyte.

What drugs are being tested in NCT01689727?

Interventions in NCT01689727: Technetium Tc 99m EC20.

What condition does NCT01689727 study?

NCT01689727 studies Pituitary Tumors.

Is NCT01689727 still recruiting?

NCT01689727 is currently completed. Last updated 20 June 2023.

Last reviewed 2023-06-20 · How we verify

NCT01689727

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Completed Phase 2 Last updated 20 June 2023

What this trial tests

Phase 2 trial testing Technetium Tc 99m EC20 in Pituitary Tumors in 40 participants. Completed.

Timeline

1 September 2002

Primary endpoint
1 September 2004

Quick facts

Lead sponsor	Endocyte
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	40
Start date	1 September 2002
Primary completion	1 September 2004
Sites	1 location across United States

Drugs / interventions tested

Technetium Tc 99m EC20 — full drug profile →

Conditions studied

Pituitary Tumors — all drugs for Pituitary Tumors →

Sponsor

Endocyte — full company profile →

Who can join

18 and older, any sex, with Pituitary Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate receptor. The study is designed as an open-label, baseline-controlled study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery.
Jurczyk M, Jelonek K, Musiał-Kulik M, Beberok A, et al · · 2021 · cited 71× · PMID 33802531 · DOI 10.3390/pharmaceutics13030326

Verify or expand the search:

Other Endocyte trials

Trials by the same sponsor.

NCT04597411 — Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer · Phase 1 · recruiting
NCT03511664 — Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer · Phase 3 · completed
NCT03042312 — Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy · Phase 2 · terminated
NCT03011320 — An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery · Phase 1 · completed
NCT01170650 — Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01689727 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Endocyte
Last refreshed: 20 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01689727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing